mm

About Jason Novak

Jason has been a consistent contributor to VectorVest and has a blended interest in technology and finance, which he has written about for over a decade. When he's not demystifying complex financial topics or sharing a quick analysis of hot stocks on a given day, you may find him on the golf course or exploring all that Northern California has to offer.
7 10, 2024

Netflix Stock is Surging in 2024, But There Are Growth Concerns: 3 Things Investors Need to See

By |2024-10-07T16:44:07+00:00October 7th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , |

Netflix shares (NFLX) have gained more than 46% through 2024 thus far, and the streaming giant’s stock has gained 4% in the past month alone. However, there are concerns as to whether or not the company can continue to grow or not. The company has given investors a look inside year-over-year (YoY) global engagement [...]

4 10, 2024

Best Penny Stocks Under 10 Cents

By |2024-10-04T23:58:02+00:00October 4th, 2024|Categories: Stock Market|Tags: |

Getting started investing with a small account can be daunting. It feels like there’s no way to gain any traction when the best blue chip dividend stocks cost hundreds of dollars per share, if not thousands. But, there are ways you can start building a stock portfolio with just a little bit of capital. Sure, [...]

4 10, 2024

Is There Still Room to Buy Palantir (PLTR) After 133% Gain YTD? 3 Things to Consider

By |2024-10-04T15:35:10+00:00October 4th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Palantir Technologies (PLTR) has been on a torrent charge through 2024 thus far, up more than 133% - and up 156% since this time last year. While the industry has a whole has boomed, this particular stock has outpaced its peers by nearly 28%.  The question is, should you still buy PLTR today, or [...]

3 10, 2024

Chevron, ExxonMobil, and Other Energy Stocks are Climbing on Middle East Conflict: Is it Time to Buy?

By |2024-10-03T16:19:12+00:00October 3rd, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

It’s like clockwork. Anytime there’s tension in the Middle East it poses a threat to the world’s oil supply, and prices surge accordingly. That’s what we’re seeing this morning for energy stocks like Chevron (CVX) and ExxonMobil (XOM). These stocks are up nearly 6% and 7% respectively in the past week, and they’re up [...]

2 10, 2024

Nike Falls 6% on Dwindling Sales and Profits in Q1 With Weak Guidance for Q2: Is it Time to Sell NKE?

By |2024-10-02T16:58:06+00:00October 2nd, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , |

Nike Inc. (NKE) is down roughly 6% Wednesday morning after the company’s earnings day Tuesday left much to be desired in the eyes of investors.  The company is still struggling to regain its footing, and after withdrawing its full-year guidance, it’s clear that the road ahead will continue to be rocky. Here’s how the [...]

1 10, 2024

Stellantis Shares Fall Amidst Forecast Cuts: While it May Be Time for Investors to Sell STLA

By |2024-10-01T17:52:27+00:00October 1st, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , , |

Shares of Stellantis NV (STLA) are down 11% in the past week as the Netherlands-based automaker was forced to lower its full-year forecast as costs are climbing while production is falling. The company was originally expecting to deliver a double-digit profit percentage for the fiscal year, but now, the profit guidance has been brought [...]

30 09, 2024

Bristol Myer Stock Gets a Bump on FDA Approval for Schizophrenia Drug: Is it Time to Buy BMY?

By |2024-09-30T17:16:15+00:00September 30th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

Late last week Bristol Myers Squibb (BMY) got a nice 8% boost after sharing news that it gained approval from the Food and Drug Administration (FDA) for its schizophrenia drug.  The stock has cooled off since and is up just shy of 4% over the past week, but it has been on a serious [...]

27 09, 2024

Accenture Gains Nearly 6% on Rising Demand for AI Solutions: 2 Other Reasons It’s Time to Buy ACN

By |2024-09-27T15:57:42+00:00September 27th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , , |

Shares of Accenture (ACN) are up just under 6% in the past week amidst hype for the company’s AI-powered performance in the fourth quarter.  The business management consultant posted adjusted earnings per share of $2.79, which matched the analyst consensus. Revenue of $16.41 billion was a 2.6% improvement year over year and ahead of [...]

26 09, 2024

Snowflake is Sinking After Announcing $2 Billion Debt Plan: Should Investors Be Concerned?

By |2024-09-26T15:58:19+00:00September 26th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , , |

Shares of Snowflake Inc. (SNOW) are down roughly 2% Thursday morning, making it a 6% loss over the past month. The latest bit of downward pressure can be attributed to the company’s announcement that it will be raising $2 billion in debt. The plan involves two separate $1 billion Senior Convertible Notes, one of [...]

25 09, 2024

GM Takes a Dip After Former Bull Downgrades the Stock: 3 Things Investors Need to Know About GM

By |2024-09-25T17:25:15+00:00September 25th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

Shares of General Motors Co. (GM) are down more than 5% so far Wednesday morning, making for a 7% loss over the past month. This comes on the heels of a once-bullish analyst changing his stance on the stock, downgrading it from the equivalent of buy to hold. Daniel Roeska with Bernstein moved his [...]

Go to Top